缺血修饰清蛋白(ischemia modified albumin,IMA)是一项早期反映心肌细胞缺血缺氧的一项敏感指标,近年来其在临床上的应用被广泛关注。大量的临床试验证实IMA对急性冠脉综合征(ACS)的诊断、排除诊断、判断预后具有重要临床意义,在临床其他领域的研究和应用也极为广泛。本文综述近年来IMA在临床中的应用新进展。1 IMA与测定方法IMA是Bar-Or等[1]在阻断冠状动脉时发现血清清蛋白N-末端序列发生改变,使其与过渡金属元素如铜、钴、镍的结 Ischemia-modified albumin (IMA) is an early indicator of cardiomyocyte hypoxia and hypoxia. It has been widely used clinically in recent years. A large number of clinical trials confirm IMA diagnosis of acute coronary syndrome (ACS), exclude diagnosis, prognosis has important clinical significance in other areas of clinical research and application is also very extensive. This article reviews the recent advances in the clinical application of IMA in recent years. 1 IMA and determination of IMA IMA is Bar-Or et al [1] in the coronary artery occlusion was found when the serum albumin N-terminal sequence changes, and its transition metal elements such as copper, cobalt, nickel junction